Advances in antidepressants for treating post-stroke depression
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Post-stroke depression (PSD) is a common and serious complication after stroke, occurring in nearly one third of stroke survivors, and affecting mortality rate, functional outcome, rehabilitation results and quality of life. However, in the common clinical practice only a minority of patients are properly treated. A relatively small number of scientific reports are available on clinical usefulness and safety of antidepressants (ADs) in PSD. Areas covered: This report provides an updated review about pharmacological state of art of PSD, including efficacy and safety of different drugs and their role on prevention, treatment and functional outcome. Expert opinion: Even if currently an antidepressant treatment can improve depressive symptoms, neither the optimal drug nor the optimal lengths of treatment, have been identified. Serotonergic drugs are preferable because of their better safety profile, but in the recent years there has been an important debate on possible association between selective serotonin reuptake inhibitor use and increased mortality. Another issue is the potential role of ADs for improving functional recovery. Newer ADs have interesting properties, in particular vortioxetine, due to its properties of enhancing cognitive functions, but further research is needed to clarify its/their role in treatment of PSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Frequency of Depression After Stroke: A Systematic Review of Observational Studies
Hackett, M. L., Yapa, C., Parag, V., & Anderson, C. S. (2005) · Stroke · doi:10.1161/01.str.0000165928.19135.35 · Cited by 1,464
Ayerbe, L., Ayis, S., Wolfe, C. D. A., & Rudd, A. G. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.107664 · Cited by 980
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Fluoxetine targets early progenitor cells in the adult brain
Encinas, J. M., Vaahtokari, A., & Enikolopov, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601992103 · Cited by 637
Depression after Stroke and Risk of Mortality: A Systematic Review and Meta-Analysis
Bartoli, F., Lillia, N., Lax, A., Crocamo, C., Mantero, V., Carrà, G., Agostoni, E., & Clerici, M. (2013) · Stroke Research and Treatment · doi:10.1155/2013/862978 · Cited by 273
Escitalopram and Enhancement of Cognitive Recovery Following Stroke
Jorge, R. E., Acion, L., Moser, D., Adams, H. P., & Robinson, R. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.185 · Cited by 218
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185
The role of cognitive dysfunction in the symptoms and remission from depression
Gonda, X., Pompili, M., Serafini, G., Carvalho, A. F., Rihmer, Z., & Dome, P. (2015) · Annals of General Psychiatry · doi:10.1186/s12991-015-0068-9 · Cited by 173
Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs
Malberg, J., & Schechter, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382223 · Cited by 167
Cited by
Post-stroke depression: A 2020 updated review
Medeiros, G. C., Roy, D., Kontos, N., & Beach, S. R. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.06.011 · Cited by 587
Post-stroke depression: Mechanisms and pharmacological treatment
Villa, R. F., Ferrari, F., & Moretti, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.005 · Cited by 532
Kiper, P., Przysiężna, E., Cieślik, B., Broniec-Siekaniec, K., Kucińska, A., Szczygieł, J., Turek, K., Gajda, R., & Szczepańska-Gieracha, J. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s375754 · Cited by 80
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Chen, F., Zhou, Q., Wu, J., & Xu, X. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04160-z · Cited by 5
“Both the changes brought about by the disease and the psychological distress can significantly reduce the quality of life [5, 6, 14], thus increasing the risk of stroke recurrence and even death [15, 16].”
Background
Metadata
- Authors
- Paolucci, S.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2017-06-05
- Volume
- 18
- Issue
- 10
- Pages
- 1011-1017
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2617632711
- Cited by
- 110
- References
- 12
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in antidepressants for treating post-stroke depression. https://app.cochat.ai/papers/10.1080/14656566.2017.1334765
- The paper
- Paolucci, S. (2017). Advances in antidepressants for treating post-stroke depression. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2017.1334765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.